Here’s a first: Regeneron cuts forecast after hard-charging Eylea sales miss

Carly Helfand Here's something Regeneron isn't used to: Cutting sales forecasts for blockbuster eye drug Eylea. But that's just what the New York biotech did Tuesday amid ...

Takeda profits fall in first half as Actos sales contract

Eric Palmer Takeda COO Christophe Weber announced a revamped management structure in September that he is building in an effort to revive the Japanese drugmaker. And from the company's ...

India’s Wockhardt profit freefalls as FDA bans devastate U.S. sales

Eric Palmer How bad can an FDA ban on plants be when the U.S. is your primary market? Really bad, India's Wockhardt found out this quarter, with its profit dropping more than $ ...

Report: Orphan drugs to nab 19% of drug sales by 2020–if payers don’t balk, that is

Carly Helfand Pharma companies have been quick to get on board with the orphan drug development trend in recent years, racing to bring pricey treatments for small patient populations ...

Arena narrows loss as Belviq sales pick up

Eric Palmer With a marketing push from partner Eisai behind it, Arena Pharmaceuticals more than doubled the revenue it earned from weight-loss drug Belviq in the last quarter but reported ...

New-drug sales boost plus OTC buyout yields $53B forecast for Bayer

Carly Helfand Bayer is already coasting along sales-wise, with some powerhouse new drugs helping it beat analysts' third-quarter forecasts. And those sales will only keep on growing, ...

Pfizer, Merck, pick up hefty vax sales bump with CDC nod in seniors

Carly Helfand Pfizer's Prevnar 13, the world's best-selling vaccine, scored a big win Wednesday, nabbing a CDC committee nod for universal use in adults over the age of 65. ...

Merck spokeswoman: Sales layoffs to hit PA-based field reps

Tracy Staton The job-cutting ax has come out for Merck's U.S. field force, as part of a move to cut 600 positions by August.  FiercePharma News

Merck whacks 600 sales reps as part of 8,500 bloodletting

Eric Palmer Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with ...

Novartis sales flag on Diovan generics, but CEO promises cost cuts will fuel profits

Tracy Staton Take a look at Novartis' second-quarter results for reasons why it engineered that big asset swap-and-sale with GlaxoSmithKline and Eli Lilly. The two units Novartis ...

U.K. court cuts Alimta exclusivity short, threatening Lilly’s European sales

Tracy Staton Eli Lilly lost a patent fight with Actavis in English High Court, in a ruling that paves the way for copycat competition not only in that country, but several others ...

AbbVie’s Humira turns in 18% surge in sales

Eric Palmer AbbVie's Humira is the gift that just keeps on giving, and it presented the still-young drugmaker with a very big boost in the first quarter, powering its sales and ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS